LEADER 03805nam  2200913z- 450 
001 9910557287703321
005 20210501
035   $a(CKB)5400000000041163
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68933
035   $a(oapen)doab68933
035   $a(EXLCZ)995400000000041163
100   $a20202105d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aPharmacogenomics and Personalized Medicine
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 online resource (208 p.)
311 08$a3-03936-730-7 
311 08$a3-03936-731-5 
330   $aPharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient's genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including a study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of inter-individual variability in drug metabolism. In this book, we have collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastructures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics.
606   $aMedicine$2bicssc
610   $aacenocoumarol
610   $aalleles
610   $aAML
610   $aazathioprine
610   $abreast cancer subtype
610   $aCDSS
610   $achildhood acute lymphoblastic leukemia
610   $acisplatin
610   $aclopidogrel
610   $acrosstalk network
610   $aCYP2C9
610   $adrug resistance
610   $afocal copy number alterations
610   $agene expression
610   $agenetic polymorphisms
610   $agenotype
610   $aglutathione-S transferase
610   $ahigh-throughput analysis
610   $ahuman genetics
610   $aimplementation
610   $ainflammatory bowel disease
610   $aINR
610   $akidney injury
610   $amicroRNAs
610   $amiRNA
610   $anephrotoxicity
610   $anucleoside analogs
610   $aovarian cancer
610   $apanel
610   $apathway
610   $apersonalized medicine
610   $apharmacogenetics
610   $apharmacogenetics study
610   $apharmacogenomics
610   $apharmacokinetics
610   $apharmacology
610   $apharmacotranscriptomics
610   $aphenotype
610   $aplatinum resistance
610   $apre-emptive
610   $aprecision drugs
610   $aprecision medicine
610   $aVKORC1
610   $awarfarin
610   $awarfarin initiation phase of therapy
610   $awhole exome sequencing
615  7$aMedicine
700   $aCecchin$b Erika$4edt$01281270
702   $aStocco$b Gabriele$4edt
702   $aCecchin$b Erika$4oth
702   $aStocco$b Gabriele$4oth
906   $aBOOK
912   $a9910557287703321
996   $aPharmacogenomics and Personalized Medicine$93018447
997   $aUNINA